• M.Gayatri Devi
• D Pavitra
• K Srinu
• N Anjali
• B Nagamani

Pulmonary drug delivery systems (PDDS) are essential in the targeted treatment of respiratory conditions such as asthma, COPD, cystic fibrosis, and lung cancer. By delivering medications directly to the lungs, these systems enhance therapeutic efficiency and minimize systemic side effects. The primary modes of drug delivery via the pulmonary route include nebulizers, metered dose inhalers (MDIs), and dry powder inhalers (DPIs). Each device has unique mechanisms and characteristics that influence drug deposition in the respiratory tract. This article provides an in-depth review of the anatomy and physiology of the respiratory system, mechanisms of drug deposition, and the advantages and limitations of each delivery device. The discussion emphasizes the evolution of inhalation therapy and highlights the critical role of PDDS in improving the management of pulmonary diseases. Advances in technology and formulation strategies continue to drive the development of more efficient and patient-friendly inhalation devices, reinforcing the pulmonary route as a preferred method for respiratory drug delivery.

COPD, MDI, DPI, Asthma

"Innovations in Pulmonary Drug Delivery: A Comprehensive Guide to Inhalation Devices", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 9, page no.e733-e742, September-2024, Available :http://www.jetir.org/papers/JETIR2409493.pdf

"Innovations in Pulmonary Drug Delivery: A Comprehensive Guide to Inhalation Devices", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 9, page no. ppe733-e742, September-2024, Available at : http://www.jetir.org/papers/JETIR2409493.pdf